Coussy, F.; Translational Research Department, Institut Curie, PSL Research University, Paris, 75005, France, Medical Oncology Department, Institut Curie, PSL Research University, Paris, 75005, France, Genetics Department, Institut Curie, PSL Research University, Paris, 75005, France
El-Botty, R.; Translational Research Department, Institut Curie, PSL Research University, Paris, 75005, France
Château-Joubert, S.; BioPôle Alfort, Ecole Nationale Vétérinaire d'Alfort, Maisons Alfort, 94704, France
Dahmani, A.; Translational Research Department, Institut Curie, PSL Research University, Paris, 75005, France
Montaudon, E.; Translational Research Department, Institut Curie, PSL Research University, Paris, 75005, France
Leboucher, S.; Institut Curie, PSL Research University, UMR3306, Orsay, 91405, France
Morisset, L.; Translational Research Department, Institut Curie, PSL Research University, Paris, 75005, France
Painsec, P.; Translational Research Department, Institut Curie, PSL Research University, Paris, 75005, France
Sourd, L.; Translational Research Department, Institut Curie, PSL Research University, Paris, 75005, France
Huguet, L.; Translational Research Department, Institut Curie, PSL Research University, Paris, 75005, France
Nemati, F.; Translational Research Department, Institut Curie, PSL Research University, Paris, 75005, France
Servely, J.-L.; BioPôle Alfort, Ecole Nationale Vétérinaire d'Alfort, Maisons Alfort, 94704, France, INRA, PHASE Department, Nouzilly, 37380, France
Larcher, T.; INRA, APEX-PAnTher, Oniris, Nantes, 44300, France
Vacher, S.; Genetics Department, Institut Curie, PSL Research University, Paris, 75005, France
Briaux, A.; Genetics Department, Institut Curie, PSL Research University, Paris, 75005, France
Reyes, C.; Translational Research Department, Institut Curie, PSL Research University, Paris, 75005, France
La Rosa, P.; INSERM, U900, Paris, 75005, France, Institut Curie, PSL Research University, Paris, 75005, France
Lucotte, G.; INSERM, U900, Paris, 75005, France, Institut Curie, PSL Research University, Paris, 75005, France
Popova, T.; Institut Curie, PSL Research University, Paris, 75005, France, INSERM U830, Paris, 75005, France
Foidart, Pierre ; Université de Liège - ULiège > Cancer-Tumours and development biology
Sounni, Nor Eddine ; Université de Liège - ULiège > Cancer-Tumours and development biology
Noël, Agnès ; Université de Liège - ULiège > Département des sciences cliniques > Labo de biologie des tumeurs et du développement
Decaudin, D.; Translational Research Department, Institut Curie, PSL Research University, Paris, 75005, France, Medical Oncology Department, Institut Curie, PSL Research University, Paris, 75005, France
Fuhrmann, L.; Department of Pathology, Institut Curie, PSL Research University, Paris, 75005, France
Salomon, A.; Department of Pathology, Institut Curie, PSL Research University, Paris, 75005, France
Reyal, F.; Surgery Department, Institut Curie, PSL Research University, Paris, 75005, France, U932, Immunity and Cancer, INSERM, Institut Curie, Paris, 75005, France
Mueller, C.; Queen's Cancer Research Institute, Queen's University, Kingston, ON K7L 3N6, Canada
Brugge, P. T.; Division of Molecular Pathology, Cancer Genomics Centre Netherlands, Netherlands Cancer Institute, Amsterdam, 1066 CX, Netherlands
Jonkers, J.; Division of Molecular Pathology, Cancer Genomics Centre Netherlands, Netherlands Cancer Institute, Amsterdam, 1066 CX, Netherlands
Poupon, M.-F.; Translational Research Department, Institut Curie, PSL Research University, Paris, 75005, France
Stern, M.-H.; Institut Curie, PSL Research University, Paris, 75005, France, INSERM U830, Paris, 75005, France
Bièche, I.; Genetics Department, Institut Curie, PSL Research University, Paris, 75005, France
Pommier, Y.; Developmental Therapeutics Branch and Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States
Marangoni, E.; Translational Research Department, Institut Curie, PSL Research University, Paris, 75005, France
A. Thomas, Y. Pommier, Targeting topoisomerase i in the era of precision medicine. Clin. Cancer Res. 25, 6581–6589 (2019).
Y. Pommier, Topoisomerase I inhibitors: Camptothecins and beyond. Nat. Rev. Cancer 6, 789–802 (2006).
Y. Pommier, M. J. O'Connor, J. de Bono, Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action. Sci. Transl. Med. 8, 362ps317 (2016).
J. Murai, S. W. Tang, E. Leo, S. A. Baechler, C. E. Redon, H. Zhang, M. Al Abo, V. N. Rajapakse, E. Nakamura, L. M. M. Jenkins, M. I. Aladjem, Y. Pommier, SLFN11 blocks stressed replication forks independently of ATR. Mol Cell 69, 371–384 (2018).
Y. Pommier, Y. Sun, S.-N. Huang, J. L. Nitiss, Roles of eukaryotic topoisomerases in transcription, replication and genomic stability. Nat. Rev. Mol. Cell Biol. 17, 703–721 (2016).
Y. Pommier, J. M. Barcelo, V. A. Rao, O. Sordet, A. G. Jobson, L. Thibaut, Z. H. Miao, J. A. Seiler, H. Zhang, C. Marchand, K. Agama, J. L. Nitiss, C. Redon, Repair of topoisomerase I-mediated DNA damage. Prog. Nucleic Acid Res. Mol. Biol. 81, 179–229 (2006).
G. Zoppoli, M. Regairaz, E. Leo, W. C. Reinhold, S. Varma, A. Ballestrero, J. H. Doroshow, Y. Pommier, Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents. Proc. Natl. Acad. Sci. U.S.A. 109, 15030–15035 (2012).
M. H. Kang, J. Wang, M. R. Makena, J.-S. Lee, N. Paz, C. P. Hall, M. M. Song, R. I. Calderon, R. E. Cruz, A. Hindle, W. Ko, J. B. Fitzgerald, D. C. Drummond, T. J. Triche, C. P. Reynolds, Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing's family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression. Clin. Cancer Res. 21, 1139–1150 (2015).
I. Kümler, N. Brünner, J. Stenvang, E. Balslev, D. L. Nielsen, A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer. Breast Cancer Res. Treat. 138, 347–358 (2013).
J. H. Burton, C. Mazcko, A. LeBlanc, J. M. Covey, J. Ji, R. J. Kinders, R. E. Parchment, C. Khanna, M. Paoloni, S. Lana, K. Weishaar, C. London, W. Kisseberth, E. Krick, D. Vail, M. Childress, J. N. Bryan, L. Barber, E. J. Ehrhart, M. Kent, T. Fan, K. Kow, N. Northup, H. Wilson-Robles, J. Tomaszewski, J. L. Holleran, M. Muzzio, J. Eiseman, J. H. Beumer, J. H. Doroshow, Y. Pommier, NCI comparative oncology program testing of non-camptothecin indenoisoquinoline topoisomerase I inhibitors in naturally occurring canine lymphoma. Clin. Cancer Res. 24, 5830–5840 (2018).
Y. Pommier, E. Leo, H. L. Zhang, C. Marchand, DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem. Biol. 17, 421–433 (2010).
S. Kummar, A. Chen, M. Gutierrez, T. D. Pfister, L. Wang, C. Redon, W. M. Bonner, W. Yutzy, Y. Zhang, R. J. Kinders, J. Ji, D. Allen, J. M. Covey, J. L. Eiseman, J. L. Holleran, J. H. Beumer, L. Rubinstein, J. Collins, J. Tomaszewski, R. Parchment, Y. Pommier, J. H. Doroshow, Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 78, 73–81 (2016).
E. Marangoni, A. Vincent-Salomon, N. Auger, A. Degeorges, F. Assayag, P. de Cremoux, L. de Plater, C. Guyader, G. De Pinieux, J.-G. Judde, M. Rebucci, C. Tran-Perennou, X. Sastre-Garau, B. Sigal-Zafrani, O. Delattre, V. Diéras, M. F. Poupon, A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin. Cancer Res. 13, 3989–3998 (2007).
E. Marangoni, C. Laurent, F. Coussy, R. El-Botty, S. Château-Joubert, J.-L. Servely, L. de Plater, F. Assayag, A. Dahmani, E. Montaudon, F. Nemati, J. Fleury, S. Vacher, D. Gentien, A. Rapinat, P. Foidart, N. E. Sounni, A. Noel, A. Vincent-Salomon, M. Lae, D. Decaudin, S. Roman-Roman, I. Bièche, M. Piccart, F. Reyal, Capecitabine efficacy is correlated with TYMP and RB1 expression in PDX established from triple-negative breast cancers. Clin. Cancer Res. 24, 2605–2615 (2018).
F. Coussy, L. de Koning, M. Lavigne, V. Bernard, B. Ouine, A. Boulai, R. El Botty, A. Dahmani, E. Montaudon, F. Assayag, L. Morisset, L. Huguet, L. Sourd, P. Painsec, C. Callens, S. Chateau-Joubert, J.-L. Servely, T. Larcher, C. Reyes, E. Girard, G. Pierron, C. Laurent, S. Vacher, S. Baulande, S. Melaabi, A. Vincent Salomon, D. Gentien, V. Dieras, I. Bieche, E. Marangoni, A large collection of integrated genomically characterized patient-derived xenografts highlighting the heterogeneity of triple-negative breast cancer. Int. J. Cancer 145, 1902–1912 (2019).
T. Popova, E. Manié, G. Rieunier, V. Caux-Moncoutier, C. Tirapo, T. Dubois, O. Delattre, B. Sigal-Zafrani, M. Bollet, M. Longy, C. Houdayer, X. Sastre-Garau, A. Vincent-Salomon, D. Stoppa-Lyonnet, M.-H. Stern, Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res. 72, 5454–5462 (2012).
T. Popova, E. Manié, D. Stoppa-Lyonnet, G. Rigaill, E. Barillot, M. H. Stern, Genome alteration Print (GAP): A tool to visualize and mine complex cancer genomic profiles obtained by SNP arrays. Genome Biol. 10, R128 (2009).
M. M. Hoppe, R. Sundar, D. S. P. Tan, A. D. Jeyasekharan, Biomarkers for homologous recombination deficiency in cancer. J. Natl. Cancer Inst. 110, 704–713 (2018).
M. Graeser, A. McCarthy, C. J. Lord, K. Savage, M. Hills, J. Salter, N. Orr, M. Parton, I. E. Smith, J. S. Reis-Filho, M. Dowsett, A. Ashworth, N. C. Turner, A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin. Cancer Res. 16, 6159–6168 (2010).
J. Barretina, G. Caponigro, N. Stransky, K. Venkatesan, A. A. Margolin, S. Kim, C. J. Wilson, J. Lehár, G. V. Kryukov, D. Sonkin, A. Reddy, M. Liu, L. Murray, M. F. Berger, J. E. Monahan, P. Morais, J. Meltzer, A. Korejwa, J. Jané-Valbuena, F. A. Mapa, J. Thibault, E. Bric-Furlong, P. Raman, A. Shipway, I. H. Engels, J. Cheng, G. K. Yu, J. Yu, P. Aspesi Jr., M. de Silva, K. Jagtap, M. D. Jones, L. Wang, C. Hatton, E. Palescandolo, S. Gupta, S. Mahan, C. Sougnez, R. C. Onofrio, T. Liefeld, L. MacConaill, W. Winckler, M. Reich, N. Li, J. P. Mesirov, S. B. Gabriel, G. Getz, K. Ardlie, V. Chan, V. E. Myer, B. L. Weber, J. Porter, M. Warmuth, P. Finan, J. L. Harris, M. Meyerson, T. R. Golub, M. P. Morrissey, W. R. Sellers, R. Schlegel, L. A. Garraway, The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603–607 (2012).
J. Murai, A. Thomas, M. Miettinen, Y. Pommier, Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies. Pharmacol. Ther. 201, 94–102 (2019).
E. Isnaldi, D. Ferraioli, L. Ferrando, S. Brohée, F. Ferrando, P. Fregatti, D. Bedognetti, A. Ballestrero, G. Zoppoli, Schlafen-11 expression is associated with immune signatures and basal-like phenotype in breast cancer. Breast Cancer Res. Treat. 177, 335–343 (2019).
A. Ertel, J. L. Dean, H. Rui, C. Liu, A. K. Witkiewicz, K. E. Knudsen, E. S. Knudsen, RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response. Cell Cycle 9, 4153–4163 (2010).
K. E. Knudsen, D. Booth, S. Naderi, Z. Sever-Chroneos, A. F. Fribourg, I. C. Hunton, J. R. Feramisco, J. Y. Wang, E. S. Knudsen, RB-dependent S-phase response to DNA damage. Mol. Cell. Biol. 20, 7751–7763 (2000).
K. R. Stengel, J. L. Dean, S. L. Seeley, C. N. Mayhew, E. S. Knudsen, RB status governs differential sensitivity to cytotoxic and molecularly-targeted therapeutic agents. Cell Cycle 7, 1095–1103 (2008).
E. E. Bosco, Y. Wang, H. Xu, J. T. Zilfou, K. E. Knudsen, B. J. Aronow, S. W. Lowe, E. S. Knudsen, The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. J. Clin. Invest. 117, 218–228 (2007).
A. K. Witkiewicz, E. S. Knudsen, Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions. Breast Cancer Res. 16, 207 (2014).
P. Foidart, C. Yip, J. Radermacher, S. Blacher, M. Lienard, L. Montero-Ruiz, E. Maquoi, E. Montaudon, S. Chateau-Joubert, J. Collignon, M. Coibion, V. Jossa, E. Marangoni, A. Noël, N. E. Sounni, G. Jerusalem, Expression of MT4-MMP, EGFR, and RB in triple-negative breast cancer strongly sensitizes tumors to erlotinib and palbociclib combination therapy. Clin. Cancer Res. 25, 1838–1850 (2019).
J. Smith, L. M. Tho, N. Xu, D. A. Gillespie, The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv. Cancer Res. 108, 73–112 (2010).
L. Marzi, L. Szabova, M. Gordon, Z. Weaver Ohler, S. K. Sharan, M. L. Beshiri, M. Etemadi, J. Murai, K. Kelly, Y. Pommier, The indenoisoquinoline TOP1 inhibitors selectively target homologous recombination-deficient and schlafen 11-positive cancer cells and synergize with olaparib. Clin. Cancer Res. 25, 6206–6216 (2019).
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), R. Peto, C. Davies, J. Godwin, R. Gray, H. C. Pan, M. Clarke, D. Cutter, S. Darby, P. McGale, C. Taylor, Y. C. Wang, J. Bergh, A. Di Leo, K. Albain, S. Swain, M. Piccart, K. Pritchard, Comparisons between different polychemotherapy regimens for early breast cancer: Meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379, 432–444 (2012).
E. A. Perez, D. W. Hillman, J. A. Mailliard, J. N. Ingle, J. M. Ryan, T. R. Fitch, K. M. Rowland, C. G. Kardinal, J. E. Krook, J. W. Kugler, S. R. Dakhil, Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. J. Clin. Oncol. 22, 2849–2855 (2004).
A. Bardia, I. A. Mayer, J. R. Diamond, R. L. Moroose, S. J. Isakoff, A. N. Starodub, N. C. Shah, J. O'Shaughnessy, K. Kalinsky, M. Guarino, V. Abramson, D. Juric, S. M. Tolaney, J. Berlin, W. A. Messersmith, A. J. Ocean, W. A. Wegener, P. Maliakal, R. M. Sharkey, S. V. Govindan, D. M. Goldenberg, L. T. Vahdat, Efficacy and safety of anti-Trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer. J. Clin. Oncol. 35, 2141–2148 (2017).
A. Bardia, I. A. Mayer, L. T. Vahdat, S. M. Tolaney, S. J. Isakoff, J. R. Diamond, J. O'Shaughnessy, R. L. Moroose, A. D. Santin, V. G. Abramson, N. C. Shah, H. S. Rugo, D. M. Goldenberg, A. M. Sweidan, R. Iannone, S. Washkowitz, R. M. Sharkey, W. A. Wegener, K. Kalinsky, Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N. Engl. J. Med. 380, 741–751 (2019).
R. W. Mutter, N. Riaz, C. K. Ng, R. Delsite, S. Piscuoglio, M. Edelweiss, L. G. Martelotto, R. A. Sakr, T. A. King, D. D. Giri, M. Drobnjak, E. Brogi, R. Bindra, G. Bernheim, R. S. Lim, P. Blecua, A. Desrichard, D. Higginson, R. Towers, R. Jiang, W. Lee, B. Weigelt, J. S. Reis-Filho, S. N. Powell, Bi-allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer. J. Pathol. 242, 165–177 (2017).
W. K. Eng, L. Faucette, R. K. Johnson, R. Sternglanz, Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol. Pharmacol. 34, 755–760 (1988).
J. Nitiss, J. C. Wang, DNA topoisomerase-targeting antitumor drugs can be studied in yeast. Proc. Natl. Acad. Sci. U.S.A. 85, 7501–7505 (1988).
C. Liu, J. J. Pouliot, H. A. Nash, Repair of topoisomerase I covalent complexes in the absence of the tyrosyl-DNA phosphodiesterase Tdp1. Proc. Natl. Acad. Sci. U.S.A. 99, 14970–14975 (2002).
A. Fedier, R. A. Steiner, V. A. Schwarz, L. Lenherr, U. Haller, D. Fink, The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells. Int. J. Oncol. 22, 1169–1173 (2003).
J. L. Boerner, N. Nechiporchik, K. L. Mueller, L. Polin, L. Heilbrun, S. A. Boerner, G. L. Zoratti, K. Stark, P. M. LoRusso, A. Burger, Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer. PLOS One 10, e0119614 (2015).
Y. Mu, J. Lou, M. Srivastava, B. Zhao, X. H. Feng, T. Liu, J. Chen, J. Huang, SLFN11 inhibits checkpointmaintenanceandhomologousrecombinationrepair.EMBORep.17,94–109(2016).
S. W. Tang, A. Thomas, J. Murai, J. B. Trepel, S. E. Bates, V. N. Rajapakse, Y. Pommier, Overcoming resistance to DNA-targeted agents by epigenetic activation of schlafen 11 (SLFN11) expression with class I histone deacetylase inhibitors. Clin. Cancer Res. 24, 1944–1953 (2018).
E. E. Gardner, B. H. Lok, V. E. Schneeberger, P. Desmeules, L. A. Miles, P. K. Arnold, A. Ni, I. Khodos, E. de Stanchina, T. Nguyen, J. Sage, J. E. Campbell, S. Ribich, N. Rekhtman, A. Dowlati, P. P. Massion, C. M. Rudin, J. T. Poirier, Chemosensitive relapse in small cell lung cancer proceeds through an EZH2-SLFN11 axis. Cancer Cell 31, 286–299 (2017).
Y. Pommier, J. N. Weinstein, M. I. Aladjem, K. W. Kohn, Chk2 molecular interaction map and rationale for Chk2 inhibitors. Clin. Cancer Res. 12, 2657–2661 (2006).
L. Marzi, K. Agama, J. Murai, S. Difilippantonio, A. James, C. J. Peer, W. D. Figg, D. Beck, M. S. A. Elsayed, M. Cushman, Y. Pommier, Novel fluoroindenoisoquinoline non-camptothecin topoisomerase I inhibitors. Mol. Cancer Ther. 17, 1694–1704 (2018).